1249 GMT - Novo Nordisk has had a constructive first quarter on many fronts, but Barclays lowers its forecasts heading into the earnings report on lower Wegovy and Ozempic volumes in the U.S. than it previously forecast. Novo Nordisk has come off the FDA drugs shortage list and introduced its NovoCare direct-to-patient pharmacy efforts. But prescriptions didn't grow to the extent the bank needed them to in order to meet its forecasts. The bank now expects group sales growth this year at 19% at constant exchange rates, below the midpoint of company guidance at 16%-24%. A guidance cut at the first-quarter earnings report is "certainly possible, although Barclays continues to believe in the long-term story. Shares fall 2.3%. (dominic.chopping@wsj.com)
(END) Dow Jones Newswires
March 31, 2025 08:49 ET (12:49 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。